Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Conte, G. Bisagni, A. Frassoldati, A. Brandes, E. Anselmi, F. Giotta, M. Aieta, V. Gebbia, A. Musolino, O. Garrone, C. Taverniti, G. Cavazzini, A. Turletti, D. Rubino, E. Picardo, A. Ferro, F. Piacentini, S. Balduzzi, R. D'amico, V. Guarneri (2017)
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.Journal of Clinical Oncology, 35
Sarika Jain, C. Santa-Maria, A. Rademaker, F. Giles, M. Cristofanilli, W. Gradishar (2017)
Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy.Journal of Clinical Oncology, 35
S. Spazzapan, P. Conte, E. Simoncini, M. Campone, M. Miller, G. Sonke (2017)
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).Annals of oncology : official journal of the European Society for Medical Oncology, 28 Suppl 6
A. Schneeweiss, V. Moebus, H. Tesch, C. Hanusch, C. Denkert, K. Luebbe, J. Huober, P. Klare, S. Kümmel, M. Untch, K. Kast, C. Jackisch, J. Thomalla, B. Heppner, J. Blohmer, M. Rezai, M. Frank, V. Nekljudova, G. Minckwitz, S. Loibl (2015)
A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).Journal of Clinical Oncology, 33
R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey Kulyk, J. Ettl, Ravi Patel, T. Pintér, Marcus Schmidt, Y. Shparyk, A. Thummala, N. Voytko, C. Fowst, Xin Huang, Sindy Kim, S. Randolph, D. Slamon (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.The Lancet. Oncology, 16 1
P. Schmid, Yeon-Hee Park, E. Muñoz-Couselo, Sung-Bae Kim, J. Sohn, S. Im, E. Holgado, Yang Wang, T. Dang, G. Aktan, J. Cortés (2017)
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.Journal of Clinical Oncology, 35
M. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, Wei Li, N. Tung, A. Armstrong, Wenting Wu, C. Goessl, S. Runswick, P. Conte (2017)
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).Journal of Clinical Oncology, 35
A. Urruticoechea, S. Im, M. Muñoz, J. Baselga, D. Yardley, S. Heeson, S. Jones, A. Knott, Hannah Douthwaite, T. Crnjević, S. Swain (2017)
Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).Journal of Clinical Oncology, 35
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap, G. Sonke, S. Paluch-Shimon, M. Campone, K. Petráková, K. Blackwell, Eric Winer, W. Janni, S. Verma, P. Conte, C. Arteaga, D. Cameron, F. Xuan, M. Miller, C. Germa, S. Hirawat, J. O’Shaughnessy (2017)
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).Journal of Clinical Oncology, 35
S. Loibl, Gustavo Werutsky, V. Nekljudova, S. Seiler, J.-U. Blohmer, C. Denkert, C. Hanusch, J. Huober, C. Jackisch, S. Kümmel, A. Schneeweiss, M. Untch, K. Rhiem, Peter Fasching, G. Minckwitz, J. Furlanetto (2017)
Impact in delay of starting chemotherapy and surgery on pCR/survival in breast cancer (BC)-pooled analysis of individual patient data from six prospectively randomized neoadjuvant trialsSenologie - Zeitschrift für Mammadiagnostik und -therapie, 15
G. Minckwitz, M. Procter, E. Azambuja, D. Zardavas, M. Benyunes, G. Viale, T. Suter, A. Arahmani, N. Rouchet, E. Clark, A. Knott, I. Láng, C. Lévy, D. Yardley, J. Bines, R. Gelber, M. Piccart, J. Baselga (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast CancerThe New England Journal of Medicine, 377
S. Adams, P. Schmid, H. Rugo, E. Winer, D. Loirat, A. Awada, D. Cescon, H. Iwata, M. Campone, R. Nanda, R. Hui, G. Curigliano, D. Toppmeyer, J. O’Shaughnessy, S. Loi, S. Paluch-Shimon, D. Card, Jing Zhao, V. Karantza, J. Cortés (2017)
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.Journal of Clinical Oncology, 35
M. Colleoni, W. Luo, P. Karlsson, J. Chirgwin, S. Aebi, G. Jerusalem, P. Neven, E. Hitre, M. Graas, E. Simoncini, C. Kamby, A. Thompson, S. Loibl, J. Gavilá, K. Kuroi, M. Gnant, M. Rabaglio-Poretti, M. Regan, A. Coates, A. Goldhirsch (2017)
SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).Journal of Clinical Oncology, 35
C. Geyer, J. O’Shaughnessy, M. Untch, W. Sikov, H. Rugo, M. McKee, J. Huober, M. Golshan, V. Giranda, G. Minckwitz, D. Maag, D. Sullivan, N. Wolmark, K. McIntyre, J. Lorenzo, O. Filho, P. Rastogi, W. Symmans, Xuan Liu, S. Loibl (2017)
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).Journal of Clinical Oncology, 35
R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey Kulyk, J. Ettl, Ravi Patel, T. Pintér, Marcus Schmidt, Y. Shparyk, A. Thummala, N. Voytko, C. Fowst, Xin Huang, Sindy Kim, D. Slamon (2017)
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).Journal of Clinical Oncology, 35
G. Sledge, M. Toi, P. Neven, J. Sohn, Kenichi Inoue, X. Pivot, O. Burdaeva, M. Okera, N. Masuda, P. Kaufman, H. Koh, E. Grischke, Martin Frenzel, Yong Lin, S. Barriga, I. Smith, N. Bourayou, A. Llombart-Cussac (2017)
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapyJournal of Clinical Oncology, 35
G. Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, C. Denkert, M. Rezai, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, D. Zahm, S. Kümmel, H. Eidtmann, P. Klare, J. Huober, S. Costa, H. Tesch, C. Hanusch, J. Hilfrich, F. Khandan, P. Fasching, B. Sinn, K. Engels, K. Mehta, V. Nekljudova, M. Untch (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.The Lancet. Oncology, 15 7
S. Adams, S. Loi, D. Toppmeyer, D. Cescon, M. Laurentiis, R. Nanda, E. Winer, H. Mukai, K. Tamura, A. Armstrong, Minetta Liu, H. Iwata, L. Ryvo, P. Wimberger, D. Card, Y. Ding, V. Karantza, P. Schmid (2017)
Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.Journal of Clinical Oncology, 35
At the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase III study to investigate the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer; while toxicity was increased in the experimental group, a significantly higher pathologic complete remission (pCR) rate was observed as well suggesting that adding carboplatin to neoadjuvant anthracycline, cyclophosphamide and taxane-containing regimens is efficacious in otherwise healthy patients. In metastatic breast cancer patients harbouring BRCA germ-line mutations, the PARP(poly [ADP-ribose] polymerase)-inhibitor olaparib was superior to conventional chemotherapy defining a potential novel treatment standard in this high-risk population. In the adjuvant setting, the APHINITY trial compared dual HER2-directed antibody therapy with trastuzumab plus pertuzumab to trastuzumab alone. A small benefit in favour of the combination was observed which was more pronounced in node-positive subjects. In hormone-receptor positive metastatic disease, several studies evaluating the role of CDK4/6 (cyclin-dependendent kinases 4 and 6) inhibitors were presented with data again indicating that adding CDK4/6 inhibitors to endocrine therapy results in a clinically relevant prolongation of progression-free survival.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Nov 13, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.